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Abstract
Background: Infectious bovine keratoconjunctivitis (IBK) in beef cattle has major wel-
fare and production implications. Effective vaccination against IBK would also reduce
antibiotic use in beef production.
Objective/Hypothesis: To evaluate the efficacy of a conditionally licensed commer-
cial IBK vaccine containing Moraxella bovoculi bacterin. Primary working hypothesis
was that animals vaccinated with 2 doses of the commercial M. bovoculi vaccine
would have a lower risk of disease.
Animals: Spring born calves at a university cow-calf herd. After excluding animals
with ocular lesions, calves eligible for prevention assessment in 2017 and 2018 were
163 (81 vaccinated, 82 unvaccinated) and 207 (105 vaccinated, 102 unvaccinated).
One hundred sixty two and two hundred and six calves completed the follow-up
period in 2017 and 2018, respectively.
Methods: A randomized controlled trial. The trial design was a 2-arm parallel trial
with a 1:1 allocation ratio.
Results: In both years, calves receiving the vaccine had more IBK. This effect was
small. The pooled risk ratio was 1.30 (95% confidence interval 0.84–2.01). The
pooled unadjusted difference in mean weight (kg) at weaning was −0.88 (95% confi-
dence interval—7.2-5.43).
Conclusions and Clinical Importance: We were unable to document that the
M. bovoculi bacterin vaccine had a protective effect for the incidence of IBK in our
single herd in a 2-year study.
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1 | INTRODUCTION
Infectious bovine keratoconjunctivitis (IBK) is a common ocular infec-
tion of beef cattle, particularly in calves. Clinical signs of IBK range in
severity from a mild conjunctivitis to severe ulceration and corneal
perforation. Recovery is common in most animals; however, perma-
nent blindness and corneal scarring can occur. IBK is not only a wel-
fare concern, but also an economic one causing decreased weight
gain.1
The main causative agent for IBK is Moraxella bovis for which
there are commercial bacterins available. Challenge studies show that
introduction of M. bovis leads to IBK.2,3 Moraxella bovoculi was identi-
fied in 2007 in IBK cases and is a putative causal organism4,5 Despite
being over 10 years since the first report, the causal role of
M. bovoculi remains unclear.1,6,7 In 2017, the first USDA conditionally
licensed product for the prevention of IBK using M. bovoculi as the
antigen base was marketed. The publicly available data to support the
conditional licenses is based on product safety, that is, no adverse
reactions, rather than prevention of IBK lesions. No publicly available
data about prevention of IBK using this product are available. As a
consequence, we conducted a trial to evaluate if the vaccine would
prevent naturally occurring IBK in a herd that consistently presents
with IBK.
The efficacy of pinkeye vaccines and treatments should be tested
against naturally occurring disease. Experimental challenge studies
might be too contrived to resemble the real-world situations.8 To
prove IBK causation by M. bovis, researchers reporting in the peer
reviewed literature have challenged by unnatural routes,9,10 used
large doses of highly virulent inoculum,11,12 limited the range of cofac-
tors11,13 and preconditioned corneas.2,12,14-21 In contrast, when
testing efficacy of Moraxella-derived vaccines challenge culture was
dropped onto the corneal surface22 or instilled into the conjunctival
sac and applied it to palpebral surfaces by cotton-tipped swab without
any preconditioning.23,24 For vaccines licensed for use in the United
States by the Department of Agriculture's Center for Veterinary Bio-
logics, it is not possible to know the approaches to challenge as these
are not publicly available.
The objective of this study was to evaluate the association
between vaccination for M. bovoculi and the cumulative incidence of
IBK and weight gain in beef calves. Our primary working hypothesis
was that, if effective, animals vaccinated with 2 doses of the condi-
tional licensed commercial M. bovoculi vaccine (USDA CVM code:
2A77.00, Addison Biological Laboratory, Inc # 355) would have a
lower risk of disease. We tested this hypothesis by assessing the
cumulative disease risk from enrollment to weaning in vaccinated and
unvaccinated animals. A secondary working hypothesis was related to
weight gain. As diagnosis of IBK can be imperfect on pasture-based
animals and IBK is strongly associated with decreased weight gain,
our working hypothesis was that if vaccination is effective, then the
mean weaning weight of animals vaccinated with conditional licensed
commercial M. bovoculi vaccine (USDA CVM code: 2A77.00, Addison
Biological Laboratory, Inc # 355) would be higher when compared to
animals that did not receive vaccine.
2 | MATERIALS AND METHODS
2.1 | Ethics statement and registration
The Animal Care and Use Committee of Iowa State University
reviewed and approved the study protocol in 2017 and 2018. The
protocol for the study conducted in 2018 was preregistered and is
available online at the Open Science Framework (doi: 10.17605/OSF.
IO/ZJ4WM). No major deviations from the approved protocol were
made during the study. The reason for not preregistering the study in
2017 is that the senior author was unaware of the availability of this
option.
2.2 | Owners and animals
Calves used in the study were owned by Iowa State University McNay
Research and Demonstration Farm. This farm was selected because it
is convenient to the study staff; we have a history of working with
the farm, and it has a consistent incidence of IBK.25-29 The farm is
located in Lucas County, Iowa, and houses approximately 260 spring-
born (February to May) Angus calves each year. IBK has been a long-
standing problem in this herd with >15% of calves affected each sea-
son.27,30 Because it is unlikely that other causes of ocular lesions
would result in disease in >15% of the herd, the definition of an IBK-
affected herd was used in the absence of other definitions.
The farm separates the calves into the management groups
defined by the predominating dam parity. These are not strictly
enforced: mostly cows 2–3 years old, 4–7 years old, more than
7 years old. In 2017, calves from the 2-year-old cows in the 2- to
3-year-old management group were not eligible to participate in this
study because this group was enrolled in another project. In 2018, all
groups were eligible for enrollment. In 2017 and 2018, all eligible cal-
ves for enrollment were spring-born and were >2 months of age with
no visible ocular lesions or scars. This eligibility was assessed without
knowledge of assignment. Any ocular lesion including tearing, blepha-
rospasm, conjunctivitis, or corneal lesions was reason for exclusion.
The McNay Farm has been used for prior IBK vaccine trials25,27,30
and a population-based cohort study28 because of the history of IBK
occurrence in the herd. The presence of M. bovoculi and M. bovis in
the herd has been documented by several previous studies.27,30,31
2.3 | Interventions
Calves received either:
• Two 2 mL doses of the commercially available M. bovoculi vaccine
(https://addisonlabs.com/product/moraxella-bovoculi-bacterin/)
administered SC (https://www.bqa.org).
• No treatment in 2017 and in 2018; two 2-mL doses of saline
administered SC.
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In the 1st year, the group decided not to include an extra injection
(ie, placebo) as we considered it unnecessary. In the 2nd year, we still
considered a saline injection unnecessary; however, during the proto-
col review stage, a reviewer requested inclusion of a saline placebo
and we did not consider it to be problematic to make this change. Our
group routinely views placebo and saline as exchangeable nonactive
controls and are unaware of evidence to suggest otherwise. An adju-
vant only placebo would not be considered exchangeable. The study
used naturally occurring IBK; therefore, no challenge model details are
required.
2.4 | Objectives
The objective was to determine if the M. bovoculi vaccine could con-
trol IBK. The primary goal was to estimate the effect of vaccination
with the conditional M. bovoculi vaccine on the cumulative incidence
of IBK. The effect estimate used is the risk ratio. The secondary
goal was to estimate the effect of vaccination with the conditional
M. bovoculi vaccine on mean weight of the vaccinated versus
unvaccinated group. The effect estimate was difference in mean
weaning weight at the end of the trial.
2.5 | Outcomes
The primary outcome was the occurrence of IBK, which was defined
as any ocular lesion, tearing, blepharospasm, conjunctivitis, corneal
lesions, or corneal scars consistent with IBK. Farm staff were trained
by the research staff to diagnose IBK. This training occurred during
enrollment sessions in this and previous years. The research and the
field staff groups evaluated eyes and discussed the definition of IBK
each year at enrollment and outcome assessment on the occasions
when they were present. At weaning, if calves were observed with
centrally located corneal opacity (ie, corneal scars) that was consid-
ered consistent with a healed IBK lesion, and they had not previously
been diagnosed with IBK, they were considered to have IBK. It was
not necessary for staff to observe a centrally located IBK ulcer to
diagnose animals with IBK as it was important to treat animals as soon
as they were diagnosed for welfare reasons. Given the consistent
occurrence of IBK in this herd, this is a pragmatic solution to manage
cattle on pasture. Farm staff were unaware of the vaccination status
of the calves. It was considered that any over-diagnosis would be
equivalent across groups. The secondary outcome was weight at
weaning.
2.6 | Sample size
The expected sample size was calculated based on the expected
cumulative incidence previously reported at McNay Farm (>30%).7
Using 3 randomized blinded trials from a systemic review of IBK vac-
cine efficacy, the risk ratio of 0.5 was used as the vaccine efficacy.6
The calculation parameters were α value of .05, power of 80% and
2-sided test with assumed independence of all enrolled units. The
resulting sample size calculation using these parameters suggested
that 120 calves were required per treatment group. As it was known
in 2017, that that only 180 calves would be eligible, a 2-year study
was planned. All spring-born calves were enrolled, which was approxi-
mately 270 animals in 2018. This enrollment meant that the study
was able to detect a smaller difference in IBK incidence than originally
planned because of the larger sample size. The sample size was calcu-
lated in Open Epi software.32
2.7 | Randomization: Sequence generation
The trial design was a 2-arm parallel trial with a 1:1 allocation ratio.
The randomization schedule was created by an investigator (AOC)
using the statistical software, R package for designing and analyzing
randomized experiments and R Foundation for Statistical Comput-
ing.33 A chute processing order sheet was created using the random-
ized schedule. Allocation was at the individual animal level.
2.8 | Randomization: Allocation concealment
At the first vaccination dose allocation, calves entered the chute and
were assessed for eligibility, that is, absence of ocular lesions, by the
farm staff without knowledge of the allocation. If no lesions were
observed, the calf was eligible to be enrolled for the first dose.
2.9 | Randomization: Implementation
Once a calf was deemed eligible by the blinded farm staff, the
research staff administered either the first dose of the vaccine or
the placebo (nothing in 2017 and a saline injection in 2018) based on
the pregenerated allocation schedule. If an animal was ineligible at 1st
enrollment, this was recorded, and no further action was taken. For
the 2nd dose of the vaccine, the animal was identified by the farm
staff and the eyes evaluated for ocular lesions again. If ocular lesions
were present, this information was recorded and the animal was
not considered eligible for subsequent analysis but still received the
allocated treatment (vaccinated or unvaccinated). The rationale for
administering the 2nd dose of the allocated treatment to animals with
ocular lesions was that, if the vaccine was ultimately found to be
effective, then these ineligible animals might still benefit from the 2nd
vaccination dose. This was based on the desire to maximize the
potential animal welfare benefits to the animals.
2.10 | Blinding (masking)
Blinding of outcome assessment was achieved by ensuring that the ani-
mal ID tags did not indicate the treatment. For an animal's vaccination
status to be known at the time of IBK diagnosis, it would require that
the McNay staff committed the allocation received at enrollment to
memory. Such knowledge is unlikely for all animals but possible for
some. The allocation sheet was also not stored on the farm so it could
not be “looked up” later. The primary outcome of interest is the treat-
ment for IBK based on the presence of clinical signs associated with
IBK such as corneal opacity, corneal ulcer, corneal perforation, or
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blepharospasm with tearing and conjunctivitis, or a scar associated with
IBK. At weaning, we collected information about the presence of cor-
neal scars (centrally placed corneal opacity) and active lesions. Again,
the allocation status was not known unless the farm staff had commit-
ted the allocation from 4 months before memory, which seems unlikely.
The calf weaning weight was collected during normal processing. The
approach to weighing is unlikely to be biased by knowledge of the
treatment received, given the pace of work and other processing
requirements. Before analysis, without knowledge of the allocation sta-
tus, the weight data were assessed for unusual observations to be
excluded, that is, abnormal weights. The association between the out-
come and the allocation status was assessed after data cleaning.
2.11 | Statistical methods
Only animals that completed enrollment, that is, no ocular lesions at
the 1st or 2nd vaccination, were included in the primary analysis. The
primary analysis for the impact of vaccination on the cumulative inci-
dence used a Mantel–Haenszel analysis stratified by year. Assessment
of effect modification by year was conducted by using the Breslow
and Day chi-square test for effect modification by year. The effect
measure reported was the Mantel–Haenszel risk ratio and 95% confi-
dence interval in each study year and pooled across the years. The
numerator for all risk ratio calculations was the incidence of IBK
in vaccinated animals and the denominator was the incidence in
unvaccinated animals. If vaccination was associated with reduced inci-
dence of IBK, the risk ratio would be <1.
The secondary analysis for weaning weight used a linear model to
assess if there was effect modification by year using a cross product
term between year and treatment, that is, did the effect of the vaccine
differ by year. A P value <.1 was considered significant. The effect
measure was mean difference in weaning weight between the vacci-
nated and unvaccinated cattle. If there was no evidence of effect
modification, then a pooled mean weaning weight was calculated. We
subtracted the mean weight of the unvaccinated calves from the vac-
cinated calves (mean weight in vaccinated calves—mean weight in
unvaccinated calves). Therefore, if the vaccinated gained more weight,
this mean difference would be positive, that is, on average more
weight gained by the vaccinated animals.
Several unplanned ancillary unplanned analyses were conducted.
We calculated the risk ratio for IBK for calves that were born before
April 1 in either year. This was done because, although we vaccinated
all animals for pragmatic disease-control reasons, the manufacturer's
label suggests calves should be 14 weeks of age at vaccination.
We calculated the mean difference and 95% confidence interval in
weaning weights of vaccinated compared to unvaccinated animals,
adjusted for weight at enrollment, study year and sex. The mean differ-
ence and 95% confidence interval in weaning weights of IBK positive
compared to IBK negative animals adjusted for study year was also cal-
culated. For all other analyses, we did not use significance testing for
the vaccine effect instead preferring to report the effect measure (risk
ratio or mean difference) and precision of the effect measure (95% con-
fidence interval).34-36 All analyses were conducted in R software.37
3 | RESULTS
3.1 | Study flow
The flow of animals born at the McNay herd in 2017 and 2018 is
reported in Table 1. The number of animals eligible at the first vacci-
nation in 2017 and 2018 was 183 and 268, respectively. The reason
for the difference in enrollment numbers is that in 2017, calves born
to young cows were participating in another study. In 2017, between
1st and 2nd vaccine doses, a larger number of animals developed IBK
in the vaccinated group than the unvaccinated group (13 versus 7). In
2018, a similar number of calves developed lesions between doses
(30 vaccinated versus 31 unvaccinated).
3.2 | Recruitment
The dates of recruitment for 1st and 2nd dose of the vaccination and
placebo are described in Table 2. Although the calves were scheduled
to receive the 2nd dose of the vaccine between 21 and 28 days after
the first dose, this was often not possible. In a decision beyond the
control of research staff, the farm staff canceled working on the cal-
ves because of welfare concerns in extreme heat during both sum-
mers. In those circumstances, the animals received the 2nd dose at
the next practical opportunity based on weather and farm staff avail-
ability. In 2017 and 2018, the calves were weaned between the 1st
and 3rd weeks of October.
3.3 | Baseline
The characteristics of the calves eligible for the study, that completed
enrollment, and that were included in the analysis are presented in
Table 1. Differences in baseline characteristics at enrollment were not
tested for significance as per recommendations.38 As some animals
did develop IBK lesions between the 1st and 2nd dose of vaccine, we
also report the baseline of the animals that completed the 2 doses. In
2017, more calves in the vaccinated group (13 of 94, 14% of those ini-
tially allocated) developed IBK between the 1st and 2nd dose than
the placebo group (7 of 89, 7% of those initially allocated).
3.4 | Numbers analyzed
One animal was lost to follow-up because of death between completion
of enrollment and completion of the study (Table 1). For the IBK out-
come, data were available for all calves. One vaccinated and 1 placebo
calf were missing an enrollment weight in 2017 and none in 2018. For
the weaning weight data, 1 calf in the placebo group had an illegible
weight record on the data sheet in 2018, so this animal was included in
the IBK data analysis but not the weaning weight data analysis.
3.5 | Outcomes and estimation
The results for the primary outcome, cumulative incidence of IBK in
both groups each year is reported in Table 1 and the pooled risk ratio
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was 1.30 with a 95% confidence interval from 0.84, to 2.01(Figure 1).
The test for heterogeneity over years was not significant (P > .1), which
is obvious when evaluating the risk ratio in 2017 and 2018, as both are
similar. The results suggest that vaccinated calves had increased risk of
IBK in both years, although the uncertainty around the estimate sug-
gests that no effect of the vaccine is also possible. The difference in risk
of disease between the vaccinated and unvaccinated animals is only
5% as shown by the risk difference scale (see Figure 1).
The results for the secondary outcome, weaning weight in vacci-
nated and unvaccinated calves are reported in Table 1. The preplanned
unadjusted analysis of vaccine effect on weaning weights is presented
in the top panel of Figure 1.
There was no evidence of an effect of the vaccine status on the
mean weaning weight. There was a significant effect of year on the
effect of vaccination of weaning weight (interaction P = .03). The differ-
ence in enrollment weights of the vaccinated and placebo calves that
completed the enrollment is only slightly different from those initially
allocated suggesting that randomization was effective for this variable
(Table 1). Each year more females were randomly allocated to the vacci-
nated group (Table 1). We present the original planned unadjusted esti-
mation approach in Table 3 for each year and combined years.
3.6 | Ancillary analyses
The pooled risk ratio of IBK incidence for calves born before April
1 was 1.27 (95% CI–0.8-1.7), which is not very different from the
analysis including all ages (Table 1). Three unplanned adjusted estima-
tion approaches with different covariates are included Table 3. It can
TABLE 2 The dates of vaccination for calves enrolled in 2-year randomized controlled trial of conditionally licensed commercial Moraxella
bovoculi bacterin trial in 2017 and 2018 in beef calves in the United States
2017 2018
Management Group 1st dose 2nd dose
Days in
between 1st dose 2nd dose
Days in
between
Two- and 3-year-old dams Not enrolled May 31, 2018 June 22, 2018 22
Old (>7 y) dams June 19, 2017 July 21, 2017 32a June 11, 2018 July 9, 2018 28
Young (4-7 y) dams June 7, 2017 June 26, 2017 19 June 13, 2018 July 19, 2018 36a
aGroup was vaccinated outside the 21- to 28-day recommended range because of rescheduling necessitated by excessive heat considered to create
welfare concerns for calves.
TABLE 1 Flow of study participants
through the study and results for the
primary outcome (infectious bovine
keratoconjunctivitis incidence) and the
secondary outcome (weaning weight) for
beef calves enrolled in a 2-year
randomized controlled trial of a
conditionally licensed commercial
Moraxella bovoculi bacterin in the
United States
Characteristics 2017 2018
Born at farm 277 286
Exclusion reason preenrollment
Enrolled in another project 75 NA
Died before enrollment 19 18
Ocular lesion at 1st vaccination 0 0
Allocated at 1st vaccination 183 268
Vaccinated Placebo Vaccinated Placebo
Allocated at 1st dose: n1 94 89 135 133
Mean summer weight kg (SD) 148 (27) 142 (29) 102 (24) 105 (24)
Female (% of n1) 49 (52%) 39 (44%) 73 (54%) 57 (43%)
Ocular lesion at 2nd dose (% of n1) 13 (14) 7 (8) 30 (22) 31 (23)
Completed 2nd enrollment n2 (% of n1) 81 (86%) 82 (92%) 105 (78%) 102 (77%)
Mean enrollment weight kg (SD) 150 (28) 143 (30) 102 (24) 108 (21)
Missing enrollment weight 1 1 0 0
Female (% of n2) 44 (54%) 36 (44%) 55 (53%) 43 (42%)
Died (% of n2) 0 1 1 0
Complete data analyzed for IBK: n3 81 81 104 102
IBK diagnosed (% of n3) 22 (27%) 17 (21%) 16 (15%) 12 (12%)
Mean weaning weight (SEM) 220 (3.18) 210 (3.69) 209 (3.07) 218 (2.90)
Missing weaning weight 0 0 0 1
Calves born before April 1 (n4) 54 43 67 76
IBK diagnosed (% of n4) 19 (35%) 13 (30%) 24 (36%) 22 (28%)
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be seen that the effect size for the vaccination status is consistently
close to the null value of zero regardless of covariates included. The
ancillary analysis of the effect of IBK on weaning weight showed
that calves with an IBK diagnosis weighed on average less than cal-
ves not diagnosed with IBK in the follow-up period (mean differ-
ence = −10.541 kg, SE 4.14, 95% confidence interval—18.6 to −2.4).
3.7 | Adverse events




The results of this 2-year study suggest that the USDA Animal and
Plant Health Inspection Service (APHIS) licensed commercially avail-
able M. bovoculi vaccine was not associated with reduced incidence of
IBK in a herd that has a consistently high incidence of IBK.
The vaccine was used in 2 conditions. In 2017, IBK lesions had
begun to occur before the full vaccination schedule was completed;
however, the majority of cases (39 of 59 cases) occurred after the
vaccination process was completed. The overall prevalence of IBK in
the herd in 2017 was 32% (59/183). In 2018, the circumstances dif-
fered, with the majority of cases (61/89, 70%) occurring between the
1st and 2nd vaccination, although the overall prevalence of IBK was
also 33% (89)/(135 + 133). These changing circumstances are associ-
ated with the nature of field trials and the realities of naturally occur-
ring IBK. Interestingly, the effect of the vaccine was not impacted by
these differences. In both years, calves eligible for prevention assess-
ment had a slightly higher risk of IBK than their unvaccinated herd
mates. This effect was very small, as can be seen in risk difference in
Figure 1.
We did not attempt to culture the organism from the eyes of cal-
ves. Historically, in this herd, M. bovis and M. bovoculi have been
recovered or identified via culture or PCR methods from active IBK
lesions suggesting that both organisms are present in the
herd.7,26,27,39 However, our group has argued against the idea that
recovery of an organism from an active lesion as an approach to
assessing the causal organism. Because eye swab specimens cannot
be acquired immediately after initiation of infection and, owing to the
potential for opportunistic secondary infection, it is not possible to
make causal inference about organisms isolated from active lesions.
As a result, we decided the best way to diagnose IBK in the calf herd
was not on the basis of organisms recovered from old lesions but
rather the clinical signs consistent with IBK, coupled with the long his-
tory of IBK in the herd and high infectivity rate.
The vaccine manufacturer's labeled protocol recommends that cal-
ves should be 14 weeks of age when vaccinated and receive 2 doses
with a 3- to 4-week interval. In our herd, such an approach is not fea-
sible because most IBK occurs in June–July–August and therefore
some calves were not 14 weeks when vaccinated; furthermore,
inclement weather prevented repeat vaccination within 21 days.
However, we did evaluate if the vaccine effect using different age
criteria and found no meaningful difference in the effect.
Randomized trials should be assessed for risk of bias in 5 domains.
For bias caused by allocation approach for this item, this study should
have a low risk of bias, as we concealed allocation until after eligibility
was assessed and used a random number generator to allocate ani-
mals to treatment. Consequently, baseline differences are caused by
random chance. We have presented adjusted and unadjusted esti-
mates for end users to consider. For a bias caused by deviations from
intended interventions, this would require differential caregiving of
animals based on vaccination status. We consider this as unlikely (low
TABLE 3 The estimate of effect of vaccination with conditionally







2017 only Vaccination 9.78 (0.25-19.3)
2018 only Vaccination −9.32 (−17.6 to −1.02)
Combined model 1 Vaccination −0.88 (−7.2 to 5.43)
Combined model 2 Vaccination, year −0.88 (−7.2 to 5.46)a
Combined model 3 Vaccination, year,
sex
0.63 (−5.6 to 6.8)a




Note: The vaccination effect size is the mean difference in weaning weight
in kg (mean weaning weight in kg in vaccinated group compared—mean
weaning weight in kg in unvaccinated group).
aAdjusted for covariates in the model.
F IGURE 1 Unadjusted risk ratio (A) and unadjusted risk
difference (B) for the effect of vaccination with 2 doses of a
commercial Moraxella bovoculi vaccine or a saline control injection on
the incidence of infectious bovine keratoconjunctivitis in Angus calves
in 2017 and 2018
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risk of bias) as the farm staff were, for the most part, unable to differ-
entially care for animals, as groups are commingled on pastures. The
risk of bias because of differential outcome assessment is also unlikely
as farm staff were unable to determine the vaccine status of the calf
when evaluating the occurrence of IBK or a corneal scarring. Another
concern related to measurement might be bias toward the null value
of the risk ratio (ie, 1) because of nondifferential measurement of the
outcome. Staff might over diagnose IBK, because the field-based
nature of the study means that research staff are not in daily atten-
dance. Such over diagnosis would be nondifferential, that is, occur
equally in both groups; it might lead to a dilution of the presence of
IBK, thus reducing the power to detect a difference. As the ancillary
analysis documents that calves diagnosed with IBK have sustainably
lower weaning weights than calves not diagnosed with IBK, this find-
ing argues against a large impact of possible misdiagnosis on the vac-
cination comparison. If a large number of calves diagnosed with IBK
did not have IBK, then the difference in weaning weight would also
have been diluted.
Finally, bias because of selective reporting is not possible as we
have reported the primary and secondary outcome of interest and
identified when the analysis is ancillary as documented in the
prepublished protocol.
The vaccine is registered with a conditional license, and therefore
explicit data of efficacy are not available. This implies that USDA
AHPIS Center for Veterinary Biologics (CVB) had made the determina-
tion that there is reasonable expectation of efficacy for the biologic
agent (the M. bovoculi antigen[s] in this case) against pinkeye hence
the label claim “for the vaccination of healthy cattle 14 weeks of age
or older against pinkeye (infectious bovine keratoconjunctivitis).” At
the time of publication, information informing the “reasonable expec-
tation” was not publicly available. These data are the first publicly
available assessment of the efficacy of this product.
4.2 | Generalizability
As with all studies, each yearly trial was a single random event and it
is essential that replicated results are available to determine if the
findings are consistent with other studies. The conclusion of CVB to
provide a conditional license would imply that the results are not con-
sistent with other evidence. If we consider this publicly available body
of work in the larger body of work about M. bovis or M. bovoculi bac-
teria's role in IBK, the results are consistent with other findings from
our group about vaccines targeting IBK, that is, no evidence of a pro-
tective effect.2,7,25,27 Further, it is possible that earlier timing of the
vaccine relative to pinkeye occurrence, with boosters given at least
2 weeks before the onset of pinkeye season might have led to differ-
ent results. In our herd, this is not feasible, but it might be in other
herds.
Across the entire body of work this might be considered robust
because this consistency occurs in considerable heterogeneity of
years, ages at vaccination, and timing of disease pressure albeit on
1 farm. If just seeking to make inferences about this product, then the
degree of uncertainty is high as it is for any product only assessed in
2 trials. The potential mechanisms of why vaccines are not protective
include the targeted organism not being causal, the immunologic
response not being protective, or the difficulty of inducing a protec-
tive response for bacteria. The results of this study provide no insights
as to the mechanism of vaccine failure. Finally, we might speculate
that had this trial indicated the product was effective, the results
could still be considered more convincing. Single studies that demon-
strate a protective effect for vaccination appear to be treated with
less skepticism than single studies that do not demonstrate an effect.
4.3 | Overall evidence
We evaluated a commercial M. bovoculi vaccine and where unable to
document that it was associated with reduced disease incidence or
increased weight gain.
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